NLSP — NLS Pharmaceutics AG Balance Sheet
0.000.00%
Last trade - 00:00- $2.97m
- $4.13m
Annual balance sheet for NLS Pharmaceutics AG, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | PROSPECTUS | 20-F | 20-F | 20-F | 20-F |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 0.22 | 0.094 | 5.43 | 8.95 | 0.898 |
| Net Total Receivables | 0.047 | 0.061 | 0.039 | 0.041 | 0.035 |
| Prepaid Expenses | |||||
| Total Current Assets | 0.382 | 0.197 | 5.72 | 9.25 | 1.82 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | — | — | 0.03 | 0.018 | 0.007 |
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 0.696 | 1.21 | 5.76 | 9.28 | 1.85 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Current Liabilities | 4.04 | 7.2 | 2.4 | 3.36 | 7.92 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Funded Status | |||||
| Total Liabilities | 6.87 | 10.2 | 5.22 | 6 | 10.7 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Other Equity | |||||
| Total Equity | -6.17 | -8.98 | 0.542 | 3.28 | -8.83 |
| Total Liabilities & Shareholders' Equity | 0.696 | 1.21 | 5.76 | 9.28 | 1.85 |
| Total Common Shares Outstanding |